We observed that AML‐CTLs, as well as AML‐Tregs from patients with TP53 mutation, demonstrate signatures associated with IFN‐α and IFN‐γ signaling compared to the corresponding population from healthy controls. This evidence concerns the gene IFNG and acute myeloid leukemia.